Indi Molecular to present at Boulder Peptide Symposium 2019
Indi Molecular, GE Collaborating on PET Imaging Agents for Guiding Immunotherapy
Indi Molecular’s Vice President R&D Operations, Heather Agnew, Ph.D., will speak at the Boulder Peptide Symposium on September 24, 2019, at the St. Julien Hotel, Boulder, CO. The presentation time is September 24 at 9:15 AM (Peptide Showcase).
GE Healthcare and Indi Molecular to collaborate on diagnostic tool for clinical management of immunotherapy patients
Precision Oncology News - May 23, 2019
NEW YORK (GenomeWeb) – Indi Molecular is collaborating with GE Healthcare on Positron Emission Tomography (PET) imaging agents ...(paywall)
Indi Molecular CEO Albert A. Luderer to Present at the 16th Annual Anglonordic Life Science Conference
Chalfont St Giles, UK & Culver City, CA, May 14 2019 - GE Healthcare and Indi Molecular, Inc, a California-based biotechnology company, have announced plans to develop immune cell-targeted Positron-Emission Tomography (PET) tracer candidates, based on Indi Molecular’s proprietary Protein Catalyzed Capture (PCC) technology.
Indi Molecular to present at TIDES: Oligonucleotide and Peptide Therapeutics
Indi Molecular’s CEO and co-founder, Albert A. Luderer, Ph.D., will present at the 16th Annual Anglonordic Life Science Conference in London on Wednesday May 8th.
Chemical Reviews Publishes Major Review of Protein-Catalyzed Capture Agent Technology
Indi Molecular’s Vice President R&D Operations, Dr. Heather Agnew, will speak at TIDES: Oligonucleotide and Peptide Therapeutics on May 22, 2019, at the Manchester Grand Hyatt, San Diego, CA.
Indi Molecular CEO Dr. Albert A. Luderer to Speak at Biotech Showcase
CULVER CITY, CA, March 8, 2019 - Chemical Reviews has published a major review of protein-catalyzed capture agent (PCC) technology.
Indi Molecular Appoints Dr. Joey Mason as Board Member
Indi Molecular’s CEO, Dr. Albert A. Luderer will speak at Biotech Showcase on January 9, 2019 at the Hilton Union Square, San Francisco, CA. The presentation time is January 9 10:30 AM and it will be held in Franciscan D (Ballroom Level).
Indi Molecular Appoints Dr. Michael T. Klimas as Senior VP Strategy & Technical Business Development
CULVER CITY, CA – August 31, 2018 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Joey Mason, M.D., as Board Member.
Indi Molecular Publishes Data on KRas in Analytical Chemistry Demonstrating Allosteric Inhibition and Accelerated Discovery Time of Indi Molecular’s Proprietary PCC Technology
CULVER CITY, CA – August 22, 2018 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Michael T. Klimas Ph.D. as senior vice president of strategy and technical business development.
Junfeng “Jafar” Wang Joins Indi Molecular as Board Member
Culver City, CA, August 3, 2018 - Indi Molecular, an emerging biotechnology company, today announced it has published preclinical data in Analytical Chemistry demonstrating the development of a barcoded rapid assay platform for the analysis of hits from PCC macrocyclic peptide library screens.
Indi Molecular and Caltech Collaborators Publish Data on Structural Modulation of a Neurodegenerative Disease Target (SOD1) with Targeted Peptides
CULVER CITY, CA – April 26, 2018 – Indi Molecular today announced it has appointed Junfeng “Jafar” Wang to its Board of Directors.
Indi Molecular Publishes Preclinical Research Data on Novel IL-17F Therapeutic Macrocyclic Peptide
CULVER CITY, CA – April 23, 2018 – Indi Molecular and Caltech today announced a paper published in Angewandte Chemie International Edition on a targeted PCC that modulates the folding of SOD1, a protein implicated in amyotrophic lateral sclerosis.
Indi Molecular Appoints Stephen Worsley Senior VP Business Development
CULVER CITY, CA – January 16, 2018 – Indi Molecular today announced that it has published preclinical research data on a Novel IL-17F therapeutic macrocyclic peptide in Chemistry – A European Journal.
Indi Molecular to present at VIB Tools & Technologies Conference
CULVER CITY, CA – December 20, 2017 – Indi Molecular, an emerging life sciences company, announced today that it has appointed Stephen Worsley as senior vice president business development.
Indi Molecular scores first funding round
Next-Generation Antibodies and Protein Analysis (2nd Edition): VIB Tools & Technologies Conference
16-17 October 2017 | Ghent, Belgium
Dr. Heather Agnew | Speaker
Indi Molecular Building Discovery Platform With Fresh Series A Financing
Chemical & Engineering News (June 30, 2017)
Indi Molecular has secured $11.5 million in Series A funding to support the development of small peptides that act like antibodies.
Indi Molecular Raises $11.5 in Series A Round
360Dx / GenomeWeb (June 30, 2017)
Indi Molecular said this week it has closed an $11.5 million Series A financing round led by Merck Ventures, Legend Capital, Sabey Corp
Indi Molecular raises $11.5M in series A to back new synthetic class in research, imaging
BioCentury (June 29, 2017)
Indi Molecular Raises $11.5M Series A to Accelerate PCC Platform Development
BioWorld Medtech (June 29, 2017)
CULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has raised a $11.5 million Series-A financing led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic corporate venture capital arm of Merck KGaA Darmstadt, Germany; Legend Capital, a venture capital/private equity fund based in Beijing; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the financing, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital will join Indi Molecular’s board. The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.